HOUSTON - nvtip -- UK healthcare innovator, RD Biomed, developed Peptest, the world's first non-invasive test for reflux, in 2007.  Since that time it has grown to global prominence. Shipping costs and wait times were a barrier to the U.S. market preventing the adoption of this direct to consumer diagnostic test. Now with Restech managing the PepsinCheck operations, the test is shipped from the U.S., processed at strategically located American labs, and results are sent back to the consumer by mail and a secure email within about a week.

Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.

More on nvtip.com

• Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
• Netverse AI to Use Less Energy: Phinge's Verified AI & Patented App-Less Platform & Hardware Will Require Less Energy, Due to its Integrated Codebase
• How to Optimize Your Website for AI Search with DeepRank AI
• New Free Science Bingo Cards Help Grade 1 Students Learn Through Play
• DeployHub Joins Catalyst Campus SDA TAP Lab

Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role.  RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."

Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."

More on nvtip.com

• Help Build an AI That Will Create Jobs, Not Eliminate Them: Phinge is Hiring in Incline Village, Nevada for its Netverse Patented App-less Technology
• Veterans Day 2025: Virginia Veterans Can Claim Free Words of Veterans Book Vouchers
• Film Festival Makes the Invisible Visible – Held in Arizona and Nevada
• Help Change the World: Phinge Is Hiring in Incline Village & Reno Nevada for its Netverse Patented App-less Technology, Verified AI & Mobile Hardware
• Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling

About Restech

At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com

About RD Biomed & Peptest

RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions.  www.peptest.co.uk

CONTACTS

Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com

Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com

www.pepsincheck.com